Skip to main content
CervoMed Inc. logo

CervoMed Inc. — Investor Relations & Filings

Ticker · CRVO ISIN · US2537484048 US Professional, scientific and technical activities
Open in API
Filings indexed 950 across all filing types
Latest filing 2026-05-18 Regulatory Filings
Country US United States of America
Listing US CRVO

About CervoMed Inc.

https://cervomed.com/

CervoMed Inc. is a clinical-stage biotechnology company that develops treatments for age-related neurologic disorders. The company focuses on neurodegenerative diseases, including Dementia with Lewy Bodies (DLB), Alzheimer's, and Huntington's disease. Its lead investigational candidate is neflamapimod, an orally administered, small molecule brain penetrant that inhibits the p38 alpha protein kinase. CervoMed's scientific approach is based on early intervention to reverse synaptic dysfunction, which is considered a reversible aspect of the neurodegenerative process, before the onset of irreversible nerve cell death. The company is advancing neflamapimod through clinical trials, including a Phase 2 study for patients with DLB.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 92% confidence The document is a Form 8-K current report filed with the SEC, containing Items 2.02 (Results of Operations and Financial Condition via an attached press release) and 7.01 (Regulation FD Disclosure). It does not itself contain full financial statements like an interim report nor is it simply announcing the publication of a report; rather, it is a regulatory filing under the Exchange Act. There is no dedicated category for SEC Form 8-K filings, so by the fallback rule it should be classified as Regulatory Filings (RNS).
2026-05-18 English
FORM 10-Q
Interim / Quarterly Report Q1 2026
2026-05-15 English
8-K - CervoMed Inc. (0001053691) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, dated April 22, 2026. It includes a press release about clinical trial data and references a presentation made available on the company's website. The document does not contain detailed financial statements or comprehensive financial analysis but rather announces recent events and disclosures. The presence of a press release and mention of a presentation suggests this is a regulatory announcement of recent company developments rather than a full financial report or earnings release. The document length is 5361 characters, which is relatively short and consistent with a regulatory filing or announcement. Therefore, the document fits best into the Regulatory Filings (RNS) category, which is the fallback for miscellaneous SEC filings like Form 8-K that do not fit other categories.
2026-04-22 English
8-K - CervoMed Inc. (0001053691) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The text includes references to a press release about clinical trial data and presentations, but does not contain detailed financial statements or comprehensive financial analysis. It also explicitly states that the information is being furnished and not filed, and includes a press release as an exhibit. The document is not an Annual Report, Interim Report, Earnings Release, or any other detailed financial report. It is a regulatory filing to disclose material events, fitting the category of Regulatory Filings (RNS). The document length is 5529 characters, which is consistent with a typical 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-03-19 English
8-K - CervoMed Inc. (0001053691) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text mentions the filing date (March 17, 2026), the company name (CervoMed Inc.), and includes sections typical of an 8-K such as Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). It references a press release with financial results for the quarter and full year ended December 31, 2025, but the actual financial data is in the press release attached as Exhibit 99.1, not in this document itself. The 8-K is a regulatory filing to announce events and furnish information, not a full financial report like an Annual Report (10-K) or Interim Report (IR). Therefore, this document fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous SEC filings that do not fit other specific categories.
2026-03-17 English
8-K - CERVOMED INC. (0001053691) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated February 18, 2026. It includes a press release about a drug candidate and references a presentation available on the company's website. The document does not contain detailed financial statements or substantive financial data but rather announces events and disclosures. The Form 8-K is a regulatory filing used to report unscheduled material events or corporate changes. Given the nature of the content and the form type, this document fits best under Regulatory Filings (RNS) as it is a general regulatory announcement and does not fit into more specific categories like earnings release or annual report.
2026-02-18 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.